Mr. Shaun Flanagan:

The simple answer around the question of pricing in Germany is that the information is not available. I can tell the Senator that on the basis of the products we have in front of us to consider, if we had €200 million we probably would not have enough money over the next five years to say "Yes" to everything. That is pretty clear.

On the question of undone work, Professor Barry has outlined the main finding. I am responsible for the application process for all new drugs. I am not responsible for the implementation of the rare diseases programme. I am not part of the rare diseases programme. I am operating outside of my comfort zone here; I am here to discuss the processes and criteria used when evaluating orphan drugs. It is my understanding that in respect of drugs the outstanding action in the plan is a separate process that would involve a rare disease committee. Professor Barry has already described that and he has been asked to chair it.